CASSIANYEECASSIAN YEE9891YEE, CASSIANProfessorprns:coAuthorOfcoauthor ofFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:address1address line 1vivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipDepartmentDivisionvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPerson7455 Fannin StHouston77054-1901TXAuthorship 1640181Authorship 1797398Authorship 1829926Authorship 1939751Authorship 194393102787680Yee C, Biondi A, Wang XH, Iscove NN, de Sousa J, Aarden LA, Wong GG, Clark SC, Messner HA, Minden MDBloodA possible autocrine role for interleukin-6 in two lymphoma cell lines. Blood. 1989 Aug 01; 74(2):798-804.Blood1989-08-01T00:00:001989A possible autocrine role for interleukin-6 in two lymphoma cell lines.18221542von Euw EM, Barrio MM, Furman D, Levy EM, Bianchini M, Peguillet I, Lantz O, Vellice A, Kohan A, Chac?n M, Yee C, Wainstok R, Mordoh JJournal of translational medicineA phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression. J Transl Med. 2008 Jan 25; 6:6.J Transl Med2008-01-25T00:00:002008A phase I clinical study of vaccination of melanoma patients with dendritic cells loaded with allogeneic apoptotic/necrotic melanoma cells. Analysis of toxicity and immune response to the vaccine and of IL-10 -1082 promoter genotype as predictor of disease progression.19270751Wallen H, Thompson JA, Reilly JZ, Rodmyre RM, Cao J, Yee CPloS oneFludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma. PLoS One. 2009; 4(3):e4749.PLoS One2009-03-09T00:00:002009Fludarabine modulates immune response and extends in vivo survival of adoptively transferred CD8 T cells in patients with metastatic melanoma.23922301Yee CClinical cancer research : an official journal of the American Association for Cancer ResearchAdoptive T-cell therapy for cancer: boutique therapy or treatment modality? Clin Cancer Res. 2013 Sep 01; 19(17):4550-2.Clin Cancer Res2013-08-06T00:00:002013Adoptive T-cell therapy for cancer: boutique therapy or treatment modality?24610736Lee JE, Lim SA, Kim TJ, Kim K, Ng J, Kim YH, Jang IJ, Oh SB, Lee JC, Yee C, Kumar V, Lee KMEuropean journal of immunologyNKG2D ligation relieves 2B4-mediated NK-cell self-tolerance in mice. Eur J Immunol. 2014 Jun; 44(6):1802-13.Eur J Immunol2014-04-16T00:00:002014NKG2D ligation relieves 2B4-mediated NK-cell self-tolerance in mice.Emergency MedicineMelanoma Medical OncologyMD AndersonJAMES PALLISONJAMES P ALLISON8659ALLISON, JAMES PProfessor3.076660.00259998530research areas1.473320.023559895coauthor of96.126625.450360similar to11152selected publicationsALAABUDAYYEHALA ABUDAYYEH9804ABUDAYYEH, ALAAssistant ProfessorADIDIABADI DIAB9901DIAB, ADIAssistant ProfessorMICHAEL ADAVIESMICHAEL A DAVIES8753DAVIES, MICHAEL AAssociate ProfessorPATRICKHWUPATRICK HWU9108HWU, PATRICKProfessorGREGORY ALIZEEGREGORY A LIZEE9130LIZEE, GREGORY AAssociate ProfessorAuthorship 2131721Authorship 2150915Authorship 2155721Authorship 2166092Authorship 2178131Authorship 2186871Authorship 2192621Authorship 2215043Authorship 2228714Authorship 2233934Authorship 2234511Authorship 2239724Authorship 2285956Authorship 2298414Authorship 2305309Authorship 2308872Authorship 23116712Authorship 23174214Authorship 23238712Authorship 23374711Authorship 23554211472922Yee C, Sutcliffe S, Messner HA, Minden MDLeukemia & lymphomaInterleukin-6 levels in the plasma of patients with lymphoma. Leuk Lymphoma. 1992 May; 7(1-2):123-9.Leuk Lymphoma1992-05-01T00:00:001992Interleukin-6 levels in the plasma of patients with lymphoma.3978503Yee C, Wong HY, Fewer HD, Rogers AGCanadian Medical Association journalTwo cases of dysphagia due to cervical spine osteophytes successfully treated surgically. Can Med Assoc J. 1985 Apr 01; 132(7):810-2.Can Med Assoc J1985-04-01T00:00:001985Two cases of dysphagia due to cervical spine osteophytes successfully treated surgically.7796672Greenberg PD, Nelson B, Gilbert M, Sing A, Yee C, Jensen M, Riddell SRCiba Foundation symposiumGenetic modification of T cell clones to improve the safety and efficacy of adoptive T cell therapy. Ciba Found Symp. 1994; 187:212-23; discussion 224-8.Ciba Found Symp1994-01-01T00:00:001994Genetic modification of T cell clones to improve the safety and efficacy of adoptive T cell therapy.8892642Yee C, Gilbert MJ, Riddell SR, Brichard VG, Fefer A, Thompson JA, Boon T, Greenberg PDJournal of immunology (Baltimore, Md. : 1950)Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus. J Immunol. 1996 Nov 01; 157(9):4079-86.J Immunol1996-11-01T00:00:001996Isolation of tyrosinase-specific CD8+ and CD4+ T cell clones from the peripheral blood of melanoma patients following in vitro stimulation with recombinant vaccinia virus.10371507Lee PP, Yee C, Savage PA, Fong L, Brockstedt D, Weber JS, Johnson D, Swetter S, Thompson J, Greenberg PD, Roederer M, Davis MMNature medicineCharacterization of circulating T cells specific for tumor-associated antigens in melanoma patients. Nat Med. 1999 Jun; 5(6):677-85.Nat Med1999-06-01T00:00:001999Characterization of circulating T cells specific for tumor-associated antigens in melanoma patients.11104805Yee C, Thompson JA, Roche P, Byrd DR, Lee PP, Piepkorn M, Kenyon K, Davis MM, Riddell SR, Greenberg PDThe Journal of experimental medicineMelanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo. J Exp Med. 2000 Dec 04; 192(11):1637-44.J Exp Med2000-12-04T00:00:002000Melanocyte destruction after antigen-specific immunotherapy of melanoma: direct evidence of t cell-mediated vitiligo.11228405Yee C, Riddell SR, Greenberg PDCurrent opinion in immunologyIn vivo tracking of tumor-specific T cells. Curr Opin Immunol. 2001 Apr; 13(2):141-6.Curr Opin Immunol2001-04-01T00:00:002001In vivo tracking of tumor-specific T cells.12427970Yee C, Thompson JA, Byrd D, Riddell SR, Roche P, Celis E, Greenberg PDProceedings of the National Academy of Sciences of the United States of AmericaAdoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells. Proc Natl Acad Sci U S A. 2002 Dec 10; 99(25):16168-73.Proc Natl Acad Sci U S A2002-11-11T00:00:002002Adoptive T cell therapy using antigen-specific CD8+ T cell clones for the treatment of patients with metastatic melanoma: in vivo persistence, migration, and antitumor effect of transferred T cells.15735047Roszkowski JJ, Lyons GE, Kast WM, Yee C, Van Besien K, Nishimura MICancer researchSimultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor. Cancer Res. 2005 Feb 15; 65(4):1570-6.Cancer Res2005-02-15T00:00:002005Simultaneous generation of CD8+ and CD4+ melanoma-reactive T cells by retroviral-mediated transfer of a single T-cell receptor.16081794Li Y, Bleakley M, Yee CJournal of immunology (Baltimore, Md. : 1950)IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response. J Immunol. 2005 Aug 15; 175(4):2261-9.J Immunol2005-08-15T00:00:002005IL-21 influences the frequency, phenotype, and affinity of the antigen-specific CD8 T cell response.16374636Lyons GE, Roszkowski JJ, Man S, Yee C, Kast WM, Nishimura MICancer immunology, immunotherapy : CIIT-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells. Cancer Immunol Immunother. 2006 Sep; 55(9):1142-50.Cancer Immunol Immunother2005-12-23T00:00:002005T-cell receptor tetramer binding or the lack there of does not necessitate antigen reactivity in T-cell receptor transduced T cells.16762731Yee CHematology/oncology clinics of North AmericaAdoptive T-cell therapy of cancer. Hematol Oncol Clin North Am. 2006 Jun; 20(3):711-33.Hematol Oncol Clin North Am2006-06-01T00:00:002006Adoptive T-cell therapy of cancer.17448240von Euw EM, Barrio MM, Furman D, Bianchini M, Levy EM, Yee C, Li Y, Wainstok R, Mordoh JJournal of translational medicineMonocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes. J Transl Med. 2007 Apr 20; 5:19.J Transl Med2007-04-20T00:00:002007Monocyte-derived dendritic cells loaded with a mixture of apoptotic/necrotic melanoma cells efficiently cross-present gp100 and MART-1 antigens to specific CD8(+) T lymphocytes.21325070Weber J, Atkins M, Hwu P, Radvanyi L, Sznol M, Yee C, Immunotherapy Task Force of the NCI Investigational Drug Steering CommitteeClinical cancer research : an official journal of the American Association for Cancer ResearchWhite paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy. Clin Cancer Res. 2011 Apr 01; 17(7):1664-73.Clin Cancer Res2011-02-15T00:00:002011White paper on adoptive cell therapy for cancer with tumor-infiltrating lymphocytes: a report of the CTEP subcommittee on adoptive cell therapy.21331153Pollack SM, Loggers ET, Rodler ET, Yee C, Jones RLSarcomaImmune-based therapies for sarcoma. Sarcoma. 2011; 2011:438940.Sarcoma2011-01-23T00:00:002011Immune-based therapies for sarcoma.21908576Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, Jing L, Marshak JO, Dong L, Carter J, Lai I, Farrar E, Byrd D, Galloway D, Yee C, Koelle DM, Nghiem PClinical cancer research : an official journal of the American Association for Cancer ResearchMerkel cell polyomavirus-specific CD8? and CD4? T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res. 2011 Nov 01; 17(21):6671-80.Clin Cancer Res2011-09-09T00:00:002011Merkel cell polyomavirus-specific CD8? and CD4? T-cell responses identified in Merkel cell carcinomas and blood.21945395Robins H, Desmarais C, Matthis J, Livingston R, Andriesen J, Reijonen H, Carlson C, Nepom G, Yee C, Cerosaletti KJournal of immunological methodsUltra-sensitive detection of rare T cell clones. J Immunol Methods. 2012 Jan 31; 375(1-2):14-9.J Immunol Methods2011-09-10T00:00:002011Ultra-sensitive detection of rare T cell clones.22359263Pollack SM, Jungbluth AA, Hoch BL, Farrar EA, Bleakley M, Schneider DJ, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee CCancerNY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma. Cancer. 2012 Sep 15; 118(18):4564-70.Cancer2012-02-22T00:00:002012NY-ESO-1 is a ubiquitous immunotherapeutic target antigen for patients with myxoid/round cell liposarcoma.22393002Chapuis AG, Thompson JA, Margolin KA, Rodmyre R, Lai IP, Dowdy K, Farrar EA, Bhatia S, Sabath DE, Cao J, Li Y, Yee CProceedings of the National Academy of Sciences of the United States of AmericaTransferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype. Proc Natl Acad Sci U S A. 2012 Mar 20; 109(12):4592-7.Proc Natl Acad Sci U S A2012-03-05T00:00:002012Transferred melanoma-specific CD8+ T cells persist, mediate tumor regression, and acquire central memory phenotype.22585852Lee SM, Yee CCancer discoveryAnother LAP in the race. Cancer Discov. 2012 Feb; 2(2):107-9.Cancer Discov2012-02-01T00:00:002012Another LAP in the race.23580577Lim SA, Kim TJ, Lee JE, Sonn CH, Kim K, Kim J, Choi JG, Choi IK, Yun CO, Kim JH, Yee C, Kumar V, Lee KMCancer researchEx vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy. Cancer Res. 2013 Apr 15; 73(8):2598-607.Cancer Res2013-04-11T00:00:002013Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.Authorship 2368964Authorship 2377571Authorship 2379323Authorship 24016211Authorship 2404512Authorship 2404541Authorship 2408611Authorship 2432823Authorship 2442164Authorship 2443691Authorship 2459051Authorship 2466337Authorship 2472483Authorship 2505422Authorship 2505537Authorship 2509073Authorship 2534811Authorship 2552173Authorship 2569088Authorship 25768412Authorship 25861614Authorship 2603087Authorship 2604832Authorship 261581131311715Chang H, Messner HA, Wang XH, Yee C, Addy L, Meharchand J, Minden MDThe Journal of clinical investigationA human lymphoma cell line with multiple immunoglobulin rearrangements. J Clin Invest. 1992 Mar; 89(3):1014-20.J Clin Invest1992-03-01T00:00:001992A human lymphoma cell line with multiple immunoglobulin rearrangements.3948167Yee C, Shiu RPCancer researchDegradation of endothelial basement membrane by human breast cancer cell lines. Cancer Res. 1986 Apr; 46(4 Pt 1):1835-9.Cancer Res1986-04-01T00:00:001986Degradation of endothelial basement membrane by human breast cancer cell lines.8046231Nagoya S, Greenberg PD, Yee C, Weisser KE, Sugawara H, Widmer MB, Slack J, Dower SK, Lupton SD, Overell RWJournal of immunology (Baltimore, Md. : 1950)Helper T cell-independent proliferation of CD8+ cytotoxic T lymphocytes transduced with an IL-1 receptor retrovirus. J Immunol. 1994 Aug 15; 153(4):1527-35.J Immunol1994-08-15T00:00:001994Helper T cell-independent proliferation of CD8+ cytotoxic T lymphocytes transduced with an IL-1 receptor retrovirus.9368780Yee C, Riddell SR, Greenberg PDCurrent opinion in immunologyProspects for adoptive T cell therapy. Curr Opin Immunol. 1997 Oct; 9(5):702-8.Curr Opin Immunol1997-10-01T00:00:001997Prospects for adoptive T cell therapy.9619278Greenberg PD, Finch RJ, Gavin MA, Kalos M, Lewinsohn DA, Lonergan M, Lord JD, Nelson BH, Ohl?n C, Sing AP, Warren EH, Yee C, Riddell SRThe cancer journal from Scientific AmericanGenetic modification of T-cell clones for therapy of human viral and malignant diseases. Cancer J Sci Am. 1998 May; 4 Suppl 1:S100-5.Cancer J Sci Am1998-05-01T00:00:001998Genetic modification of T-cell clones for therapy of human viral and malignant diseases.9933169Li L, Yee C, Beavo JAScience (New York, N.Y.)CD3- and CD28-dependent induction of PDE7 required for T cell activation. Science. 1999 Feb 05; 283(5403):848-51.Science1999-02-05T00:00:001999CD3- and CD28-dependent induction of PDE7 required for T cell activation.9973498Yee C, Savage PA, Lee PP, Davis MM, Greenberg PDJournal of immunology (Baltimore, Md. : 1950)Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J Immunol. 1999 Feb 15; 162(4):2227-34.J Immunol1999-02-15T00:00:001999Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers.12189383Yee C, Greenberg PNature reviews. CancerModulating T-cell immunity to tumours: new strategies for monitoring T-cell responses. Nat Rev Cancer. 2002 Jun; 2(6):409-19.Nat Rev Cancer2002-06-01T00:00:002002Modulating T-cell immunity to tumours: new strategies for monitoring T-cell responses.12384702Groh V, Wu J, Yee C, Spies TNatureTumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 2002 Oct 17; 419(6908):734-8.Nature2002-10-17T00:00:002002Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation.12584044Yee CClinical immunology (Orlando, Fla.)Adoptive T cell therapy--immune monitoring and MHC multimers. Clin Immunol. 2003 Jan; 106(1):5-9.Clin Immunol2003-01-01T00:00:002003Adoptive T cell therapy--immune monitoring and MHC multimers.12781360Ho WY, Blattman JN, Dossett ML, Yee C, Greenberg PDCancer cellAdoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction. Cancer Cell. 2003 May; 3(5):431-7.Cancer Cell2003-05-01T00:00:002003Adoptive immunotherapy: engineering T cell responses as biologic weapons for tumor mass destruction.15128778Danke NA, Koelle DM, Yee C, Beheray S, Kwok WWJournal of immunology (Baltimore, Md. : 1950)Autoreactive T cells in healthy individuals. J Immunol. 2004 May 15; 172(10):5967-72.J Immunol2004-05-15T00:00:002004Autoreactive T cells in healthy individuals.15824323Groh V, Li YQ, Cioca D, Hunder NN, Wang W, Riddell SR, Yee C, Spies TProceedings of the National Academy of Sciences of the United States of AmericaEfficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells. Proc Natl Acad Sci U S A. 2005 May 03; 102(18):6461-6.Proc Natl Acad Sci U S A2005-04-11T00:00:002005Efficient cross-priming of tumor antigen-specific T cells by dendritic cells sensitized with diverse anti-MICA opsonized tumor cells.17921346Li Y, Yee CBloodIL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes. Blood. 2008 Jan 01; 111(1):229-35.Blood2007-10-05T00:00:002007IL-21 mediated Foxp3 suppression leads to enhanced generation of antigen-specific CD8+ cytotoxic T lymphocytes.18528851Gunn J, Wallen H, Veiseh O, Sun C, Fang C, Cao J, Yee C, Zhang MSmall (Weinheim an der Bergstrasse, Germany)A multimodal targeting nanoparticle for selectively labeling T cells. Small. 2008 Jun; 4(6):712-5.Small2008-06-01T00:00:002008A multimodal targeting nanoparticle for selectively labeling T cells.18563180Shah KV, Chien AJ, Yee C, Moon RTThe Journal of investigative dermatologyCTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors. J Invest Dermatol. 2008 Dec; 128(12):2870-9.J Invest Dermatol2008-06-19T00:00:002008CTLA-4 is a direct target of Wnt/beta-catenin signaling and is expressed in human melanoma tumors.20483791Abdul-Alim CS, Li Y, Yee CJournal of immunology (Baltimore, Md. : 1950)Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses. J Immunol. 2010 Jun 01; 184(11):6514-21.J Immunol2010-05-07T00:00:002010Conditional superagonist CTL ligands for the promotion of tumor-specific CTL responses.20693849Yee CCancer journal (Sudbury, Mass.)Adoptive therapy using antigen-specific T-cell clones. Cancer J. 2010 Jul-Aug; 16(4):367-73.Cancer J2010-07-01T00:00:002010Adoptive therapy using antigen-specific T-cell clones.21390072Tanaka A, Jensen JD, Prado R, Riemann H, Shellman YG, Norris DA, Chin L, Yee C, Fujita MGene therapyWhole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma. Gene Ther. 2011 Aug; 18(8):827-34.Gene Ther2011-03-10T00:00:002011Whole recombinant yeast vaccine induces antitumor immunity and improves survival in a genetically engineered mouse model of melanoma.22384167Pollack SM, Li Y, Blaisdell MJ, Farrar EA, Chou J, Hoch BL, Loggers ET, Rodler E, Eary JF, Conrad EU, Jones RL, Yee CPloS oneNYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine. PLoS One. 2012; 7(2):e32165.PLoS One2012-02-27T00:00:002012NYESO-1/LAGE-1s and PRAME are targets for antigen specific T cells in chondrosarcoma following treatment with 5-Aza-2-deoxycitabine.23447018Chapuis AG, Ragnarsson GB, Nguyen HN, Chaney CN, Pufnock JS, Schmitt TM, Duerkopp N, Roberts IM, Pogosov GL, Ho WY, Ochsenreither S, W?lfl M, Bar M, Radich JP, Yee C, Greenberg PDScience translational medicineTransferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients. Sci Transl Med. 2013 Feb 27; 5(174):174ra27.Sci Transl Med2013-02-27T00:00:002013Transferred WT1-reactive CD8+ T cells can mediate antileukemic activity and persist in post-transplant patients.23851683Goodridge JP, Lee N, Burian A, Pyo CW, Tykodi SS, Warren EH, Yee C, Riddell SR, Geraghty DEJournal of immunology (Baltimore, Md. : 1950)HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway. J Immunol. 2013 Aug 15; 191(4):1567-77.J Immunol2013-07-12T00:00:002013HLA-F and MHC-I open conformers cooperate in a MHC-I antigen cross-presentation pathway.24434638Park B, Yee C, Lee KMInternational journal of molecular sciencesThe effect of radiation on the immune response to cancers. Int J Mol Sci. 2014 Jan 10; 15(1):927-43.Int J Mol Sci2014-01-10T00:00:002014The effect of radiation on the immune response to cancers.24769442Noh KH, Kim SH, Kim JH, Song KH, Lee YH, Kang TH, Han HD, Sood AK, Ng J, Kim K, Sonn CH, Kumar V, Yee C, Lee KM, Kim TWCancer researchAPI5 confers tumoral immune escape through FGF2-dependent cell survival pathway. Cancer Res. 2014 Jul 01; 74(13):3556-66.Cancer Res2014-04-25T00:00:002014API5 confers tumoral immune escape through FGF2-dependent cell survival pathway.Authorship 2633901Authorship 2635923Authorship 2658382Authorship 26833710Authorship 2705567Authorship 27109010Authorship 27220611918171Yee CS, Messner HA, Minden MDJournal of cellular physiologyRegulation of interleukin-6 expression in the lymphoma cell line OCI-LY3. J Cell Physiol. 1991 Sep; 148(3):426-9.J Cell Physiol1991-09-01T00:00:001991Regulation of interleukin-6 expression in the lymphoma cell line OCI-LY3.2302659Andersson BS, Luna MA, Yee C, Hui KK, Keating MJ, McCredie KBCancerFatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia. Cancer. 1990 Mar 01; 65(5):1079-84.Cancer1990-03-01T00:00:001990Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia.12438439Ho WY, Yee C, Greenberg PDThe Journal of clinical investigationAdoptive therapy with CD8(+) T cells: it may get by with a little help from its friends. J Clin Invest. 2002 Nov; 110(10):1415-7.J Clin Invest2002-11-01T00:00:002002Adoptive therapy with CD8(+) T cells: it may get by with a little help from its friends.18565862Hunder NN, Wallen H, Cao J, Hendricks DW, Reilly JZ, Rodmyre R, Jungbluth A, Gnjatic S, Thompson JA, Yee CThe New England journal of medicineTreatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1. N Engl J Med. 2008 Jun 19; 358(25):2698-703.N Engl J Med2008-06-19T00:00:002008Treatment of metastatic melanoma with autologous CD4+ T cells against NY-ESO-1.22306901Chou J, Voong LN, Mortales CL, Towlerton AM, Pollack SM, Chen X, Yee C, Robbins PF, Warren EHJournal of immunotherapy (Hagerstown, Md. : 1997)Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer. J Immunother. 2012 Feb-Mar; 35(2):131-41.J Immunother2012-02-01T00:00:002012Epigenetic modulation to enable antigen-specific T-cell therapy of colorectal cancer.22784189Kim K, An HJ, Jun SH, Kim TJ, Lim SA, Park G, Na HB, Park YI, Hyeon T, Yee C, Bluestone JA, Kim J, Lee KMNano lettersSingle step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers. Nano Lett. 2012 Aug 08; 12(8):4018-24.Nano Lett2012-07-26T00:00:002012Single step isolation and activation of primary CD3+ T lymphocytes using alcohol-dispersed electrospun magnetic nanofibers.24329802Yee CImmunological reviewsThe use of endogenous T cells for adoptive transfer. Immunol Rev. 2014 Jan; 257(1):250-63.Immunol Rev2014-01-01T00:00:002014The use of endogenous T cells for adoptive transfer.Authorship 2738646Authorship 277516715120337Liao X, Li Y, Bonini C, Nair S, Gilboa E, Greenberg PD, Yee CMolecular therapy : the journal of the American Society of Gene TherapyTransfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes. Mol Ther. 2004 May; 9(5):757-64.Mol Ther2004-05-01T00:00:002004Transfection of RNA encoding tumor antigens following maturation of dendritic cells leads to prolonged presentation of antigen and the generation of high-affinity tumor-reactive cytotoxic T lymphocytes.20926796Hanaoka N, Jabri B, Dai Z, Ciszewski C, Stevens AM, Yee C, Nakakuma H, Spies T, Groh VJournal of immunology (Baltimore, Md. : 1950)NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease. J Immunol. 2010 Nov 15; 185(10):5732-42.J Immunol2010-10-06T00:00:002010NKG2D initiates caspase-mediated CD3zeta degradation and lymphocyte receptor impairments associated with human cancer and autoimmune disease.Authorship 28850615Authorship 302141324432305Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, Lai I, Roberts IM, Sloan HL, Bhatia S, Shibuya KC, Gooley T, Desmarais C, Koelle DM, Yee C, Nghiem PCancer immunology researchRegression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res. 2014 Jan; 2(1):27-36.Cancer Immunol Res2014-01-01T00:00:002014Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I.26588682Yee C, Lizee G, Schueneman AJCancer journal (Sudbury, Mass.)Endogenous T-Cell Therapy: Clinical Experience. Cancer J. 2015 Nov-Dec; 21(6):492-500.Cancer J2015-11-01T00:00:002015Endogenous T-Cell Therapy: Clinical Experience.74Professor10Assistant Professor54Instructor14Associate Professor42Director6Adjunct ProfessorYINGMAYING MA11760MA, YINGInstructorAuthorship 841709Authorship 843996Authorship 844561Authorship 845888Authorship 848364Authorship 849082Authorship 851262Authorship 851412Authorship 852933Authorship 855064Authorship 856606Authorship 857021Authorship 860724Authorship 864185Authorship 866120Authorship 866530Cellular ImmunologyInterleukin-21 administration leads to enhanced antigen-specific T cell responses and natural killer cells in HIV-1 vaccinated mice. Cellular Immunology. Interleukin-21 administration leads to enhanced antigen-specific T cell responses and natural killer cells in HIV-1 vaccinated miceFASEB JournalGenetic modification of T cell clones for therapy of human viral and malignant diseases. FASEB Journal. 11.Genetic modification of T cell clones for therapy of human viral and malignant diseasesJournal of Translational MedicineFuture perspectives in melanoma research. Journal of Translational Medicine. 14.Future perspectives in melanoma researchEuropean Cytokine NetworkTherapy of human viral and malignant diseases with gene-modified T cell clones. European Cytokine Network. 11:304-305.Therapy of human viral and malignant diseases with gene-modified T cell clonesMonitoring antigen-specific responses in clinical trials of cancer immunotherapy. 425-453.Monitoring antigen-specific responses in clinical trials of cancer immunotherapyCancer Journal (United States)Endogenous t-cell therapy. Cancer Journal (United States). 21:492-500.Endogenous t-cell therapyAdoptive therapy using antigen-specific T-cell clones. Adoptive therapy using antigen-specific T-cell clonesJournal for ImmunoTherapy of CancerTetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8<sup>+</sup> T cells. Journal for ImmunoTherapy of Cancer. 2.Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8<sup>+</sup> T cellsUpdate on Cancer TherapeuticsRecent advances in the use of antigen-specific T cells for the treatment of cancer. Update on Cancer Therapeutics. 1:333-342.Recent advances in the use of antigen-specific T cells for the treatment of cancerAdvanced Functional MaterialsEthanol-dispersed polymer nanofibers as a highly selective cell isolation and release platform for CD4 <sup>+</sup> T lymphocytes. Advanced Functional Materials. 22:4448-4455.Ethanol-dispersed polymer nanofibers as a highly selective cell isolation and release platform for CD4 <sup>+</sup> T lymphocytesJournal of Translational MedicineAdoptive T cell therapy. Journal of Translational Medicine. 3.Adoptive T cell therapyJournal of Clinical OncologyT-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regression. Journal of Clinical Oncology. 34:3787-3795.T-cell therapy using interleukin-21-primed cytotoxic T-cell lymphocytes combined with cytotoxic T-cell lymphocyte antigen-4 blockade results in long-term cell persistence and durable tumor regressionAdoptive cellular therapy for the treatment of cancer. 343-361.Adoptive cellular therapy for the treatment of cancerJournal of Experimental MedicineCombined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. Journal of Experimental Medicine. 213:1133-1139.Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patientJournal for ImmunoTherapy of CancerHighlights of the society for immunotherapy of cancer (SITC) 27th annual meeting. Journal for ImmunoTherapy of Cancer. 1.Highlights of the society for immunotherapy of cancer (SITC) 27th annual meetingAdoptive immunotherapy of melanoma. 439-465.Adoptive immunotherapy of melanomaD000951Chemicals & Drugs50015010.601033Antigens, NeoplasmD016219Procedures37817300.485543Immunotherapy, AdoptiveD018414Anatomy56915760.568005CD8-Positive T-LymphocytesAuthorship 8964081Authorship 9020469Authorship 90265913Authorship 90282010Authorship 90302314Authorship 90766014Authorship 90778215Authorship 90830118Authorship 9091669Authorship 91404115Authorship 91509413Authorship 91697114Authorship 91784428Authorship 9202958Authorship 92077111Authorship 9216051Authorship 92362915Authorship 92666219Authorship 9270721Authorship 9274186Authorship 9278231Authorship 92856828Authorship 9311729Authorship 93180317Authorship 9344389Authorship 9399831315860133Yee CJournal of translational medicineAdoptive T cell therapy: Addressing challenges in cancer immunotherapy. J Transl Med. 2005 Apr 28; 3(1):17.J Transl Med2005-04-28T00:00:002005Adoptive T cell therapy: Addressing challenges in cancer immunotherapy.23996980Park G, Chung HJ, Kim K, Lim SA, Kim J, Kim YS, Liu Y, Yeo WH, Kim RH, Kim SS, Kim JS, Jung YH, Kim TI, Yee C, Rogers JA, Lee KMAdvanced healthcare materialsImmunologic and tissue biocompatibility of flexible/stretchable electronics and optoelectronics. Adv Healthc Mater. 2014 Apr; 3(4):515-25.Adv Healthc Mater2013-09-01T00:00:002013Immunologic and tissue biocompatibility of flexible/stretchable electronics and optoelectronics.24684516Hwang SW, Park G, Edwards C, Corbin EA, Kang SK, Cheng H, Song JK, Kim JH, Yu S, Ng J, Lee JE, Kim J, Yee C, Bhaduri B, Su Y, Omennetto FG, Huang Y, Bashir R, Goddard L, Popescu G, Lee KM, Rogers JAACS nanoDissolution chemistry and biocompatibility of single-crystalline silicon nanomembranes and associated materials for transient electronics. ACS Nano. 2014 Jun 24; 8(6):5843-51.ACS Nano2014-04-09T00:00:002014Dissolution chemistry and biocompatibility of single-crystalline silicon nanomembranes and associated materials for transient electronics.24794217Shibuya KC, Goel VK, Xiong W, Sham JG, Pollack SM, Leahy AM, Whiting SH, Yeh MM, Yee C, Riddell SR, Pillarisetty VGPloS onePancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment. PLoS One. 2014; 9(5):e96565.PLoS One2014-05-02T00:00:002014Pancreatic ductal adenocarcinoma contains an effector and regulatory immune cell infiltrate that is altered by multimodal neoadjuvant treatment.25475707Kim TJ, Kim M, Kim HM, Lim SA, Kim EO, Kim K, Song KH, Kim J, Kumar V, Yee C, Doh J, Lee KMScientific reportsHomotypic NK cell-to-cell communication controls cytokine responsiveness of innate immune NK cells. Sci Rep. 2014 Dec 05; 4:7157.Sci Rep2014-12-05T00:00:002014Homotypic NK cell-to-cell communication controls cytokine responsiveness of innate immune NK cells.25317334Pollack SM, Jones RL, Farrar EA, Lai IP, Lee SM, Cao J, Pillarisetty VG, Hoch BL, Gullett A, Bleakley M, Conrad EU, Eary JF, Shibuya KC, Warren EH, Carstens JN, Heimfeld S, Riddell SR, Yee CJournal for immunotherapy of cancerTetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells. J Immunother Cancer. 2014; 2(1):36.J Immunother Cancer2014-10-14T00:00:002014Tetramer guided, cell sorter assisted production of clinical grade autologous NY-ESO-1 specific CD8(+) T cells.27062692Ju B, Li D, Ji X, Liu J, Peng H, Wang S, Liu Y, Hao Y, Yee C, Liang H, Shao YCellular immunologyInterleukin-21 administration leads to enhanced antigen-specific T cell responses and natural killer cells in HIV-1 vaccinated mice. Cell Immunol. 2016 05; 303:55-65.Cell Immunol2016-04-01T00:00:002016Interleukin-21 administration leads to enhanced antigen-specific T cell responses and natural killer cells in HIV-1 vaccinated mice.27269940Chapuis AG, Roberts IM, Thompson JA, Margolin KA, Bhatia S, Lee SM, Sloan HL, Lai IP, Farrar EA, Wagener F, Shibuya KC, Cao J, Wolchok JD, Greenberg PD, Yee CJournal of clinical oncology : official journal of the American Society of Clinical OncologyT-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression. J Clin Oncol. 2016 11 01; 34(31):3787-3795.J Clin Oncol2016-11-01T00:00:002016T-Cell Therapy Using Interleukin-21-Primed Cytotoxic T-Cell Lymphocytes Combined With Cytotoxic T-Cell Lymphocyte Antigen-4 Blockade Results in Long-Term Cell Persistence and Durable Tumor Regression.27242164Chapuis AG, Lee SM, Thompson JA, Roberts IM, Margolin KA, Bhatia S, Sloan HL, Lai I, Wagener F, Shibuya K, Cao J, Wolchok JD, Greenberg PD, Yee CThe Journal of experimental medicineCombined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient. J Exp Med. 2016 06 27; 213(7):1133-9.J Exp Med2016-05-30T00:00:002016Combined IL-21-primed polyclonal CTL plus CTLA4 blockade controls refractory metastatic melanoma in a patient.27846884Ascierto PA, Agarwala S, Botti G, Cesano A, Ciliberto G, Davies MA, Demaria S, Dummer R, Eggermont AM, Ferrone S, Fu YX, Gajewski TF, Garbe C, Huber V, Khleif S, Krauthammer M, Lo RS, Masucci G, Palmieri G, Postow M, Puzanov I, Silk A, Spranger S, Stroncek DF, Tarhini A, Taube JM, Testori A, Wang E, Wargo JA, Yee C, Zarour H, Zitvogel L, Fox BA, Mozzillo N, Marincola FM, Thurin MJournal of translational medicineFuture perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015. J Transl Med. 2016 11 15; 14(1):313.J Transl Med2016-11-15T00:00:002016Future perspectives in melanoma research : Meeting report from the "Melanoma Bridge". Napoli, December 1st-4th 2015.28367538Chapuis AG, Desmarais C, Emerson R, Schmitt TM, Shibuya K, Lai I, Wagener F, Chou J, Roberts IM, Coffey DG, Warren E, Robbins H, Greenberg PD, Yee CScience immunologyTracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo. Sci Immunol. 2017 Feb; 2(8).Sci Immunol2017-02-24T00:00:002017Tracking the Fate and Origin of Clinically Relevant Adoptively Transferred CD8+ T Cells In Vivo.28716899Song KH, Choi CH, Lee HJ, Oh SJ, Woo SR, Hong SO, Noh KH, Cho H, Chung EJ, Kim JH, Chung JY, Hewitt SM, Baek S, Lee KM, Yee C, Son M, Mao CP, Wu TC, Kim TWCancer researchHDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells. Cancer Res. 2017 09 15; 77(18):5039-5053.Cancer Res2017-07-17T00:00:002017HDAC1 Upregulation by NANOG Promotes Multidrug Resistance and a Stem-like Phenotype in Immune Edited Tumor Cells.28410295Yee CCancer journal (Sudbury, Mass.)From the Guest Editor. Cancer J. 2017 Mar/Apr; 23(2):95-96.Cancer J2017-03-01T00:00:002017From the Guest Editor.28410303Yee C, Lizee GACancer journal (Sudbury, Mass.)Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy. Cancer J. 2017 Mar/Apr; 23(2):144-148.Cancer J2017-03-01T00:00:002017Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy.28630054Park J, Talukder AH, Lim SA, Kim K, Pan K, Melendez B, Bradley SD, Jackson KR, Khalili JS, Wang J, Creasy C, Pan BF, Woodman SE, Bernatchez C, Hawke D, Hwu P, Lee KM, Roszik J, Liz?e G, Yee CCancer immunology researchSLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity. Cancer Immunol Res. 2017 08; 5(8):618-629.Cancer Immunol Res2017-06-19T00:00:002017SLC45A2: A Melanoma Antigen with High Tumor Selectivity and Reduced Potential for Autoimmune Toxicity.28630682Roszik J, Wang WL, Livingston JA, Roland CL, Ravi V, Yee C, Hwu P, Futreal A, Lazar AJ, Patel SR, Conley APClinical sarcoma researchOverexpressed PRAME is a potential immunotherapy target in sarcoma subtypes. Clin Sarcoma Res. 2017; 7:11.Clin Sarcoma Res2017-06-15T00:00:002017Overexpressed PRAME is a potential immunotherapy target in sarcoma subtypes.29387478Glitza IC, Rohlfs M, Guha-Thakurta N, Bassett RL, Bernatchez C, Diab A, Woodman SE, Yee C, Amaria RN, Patel SP, Tawbi H, Wong M, Hwu WJ, Hwu P, Heimberger A, McCutcheon IE, Papadopoulos N, Davies MAESMO openRetrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2. ESMO Open. 2018; 3(1):e000283.ESMO Open2018-01-24T00:00:002018Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2.29599906Wolff RA, Wang-Gillam A, Alvarez H, Tiriac H, Engle D, Hou S, Groff AF, San Lucas A, Bernard V, Allenson K, Castillo J, Kim D, Mulu F, Huang J, Stephens B, Wistuba II, Katz M, Varadhachary G, Park Y, Hicks J, Chinnaiyan A, Scampavia L, Spicer T, Gerhardinger C, Maitra A, Tuveson D, Rinn J, Lizee G, Yee C, Levine AJOncotargetDynamic changes during the treatment of pancreatic cancer. Oncotarget. 2018 Mar 13; 9(19):14764-14790.Oncotarget2018-02-13T00:00:002018Dynamic changes during the treatment of pancreatic cancer.29669940Mendt M, Kamerkar S, Sugimoto H, McAndrews KM, Wu CC, Gagea M, Yang S, Blanko EVR, Peng Q, Ma X, Marszalek JR, Maitra A, Yee C, Rezvani K, Shpall E, LeBleu VS, Kalluri RJCI insightGeneration and testing of clinical-grade exosomes for pancreatic cancer. JCI Insight. 2018 04 19; 3(8).JCI Insight2018-04-19T00:00:002018Generation and testing of clinical-grade exosomes for pancreatic cancer.29437706Oh SJ, Cho H, Kim S, Noh KH, Song KH, Lee HJ, Woo SR, Kim S, Choi CH, Chung JY, Hewitt SM, Kim JH, Baek S, Lee KM, Yee C, Park HC, Kim TWCancer researchTargeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis. Cancer Res. 2018 05 15; 78(10):2638-2653.Cancer Res2018-02-06T00:00:002018Targeting Cyclin D-CDK4/6 Sensitizes Immune-Refractory Cancer by Blocking the SCP3-NANOG Axis.29730057Yee CCurrent opinion in immunologyAdoptive T cell therapy: points to consider. Curr Opin Immunol. 2018 04; 51:197-203.Curr Opin Immunol2018-05-02T00:00:002018Adoptive T cell therapy: points to consider.30124467Song KH, Kim JH, Lee YH, Bae HC, Lee HJ, Woo SR, Oh SJ, Lee KM, Yee C, Kim BW, Cho H, Chung EJ, Chung JY, Hewitt SM, Chung TW, Ha KT, Bae YK, Mao CP, Yang A, Wu TC, Kim TWThe Journal of clinical investigationMitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance. J Clin Invest. 2018 08 31; 128(9):4098-4114.J Clin Invest2018-08-20T00:00:002018Mitochondrial reprogramming via ATP5H loss promotes multimodal cancer therapy resistance.29791021Zhang H, Li Y, Liu X, Liang Z, Yan M, Liu Q, Chen A, Bao Y, Zhou C, Li S, Yee C, Li YImmunologyImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression. Immunology. 2018 10; 155(2):238-250.Immunology2018-06-14T00:00:002018ImmTAC/Anti-PD-1 antibody combination to enhance killing of cancer cells by reversing regulatory T-cell-mediated immunosuppression.30651129Choi HY, Yang GM, Dayem AA, Saha SK, Kim K, Yoo Y, Hong K, Kim JH, Yee C, Lee KM, Cho SGBreast cancer research : BCRHydrodynamic shear stress promotes epithelial-mesenchymal transition by downregulating ERK and GSK3? activities. Breast Cancer Res. 2019 01 16; 21(1):6.Breast Cancer Res2019-01-16T00:00:002019Hydrodynamic shear stress promotes epithelial-mesenchymal transition by downregulating ERK and GSK3? activities.30305177Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab AJournal for immunotherapy of cancerInfliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2018 10 11; 6(1):103.J Immunother Cancer2018-10-11T00:00:002018Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.30612580Mamlouk O, Selamet U, Machado S, Abdelrahim M, Glass WF, Tchakarov A, Gaber L, Lahoti A, Workeneh B, Chen S, Lin J, Abdel-Wahab N, Tayar J, Lu H, Suarez-Almazor M, Tannir N, Yee C, Diab A, Abudayyeh AJournal for immunotherapy of cancerNephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience. J Immunother Cancer. 2019 01 06; 7(1):2.J Immunother Cancer2019-01-06T00:00:002019Nephrotoxicity of immune checkpoint inhibitors beyond tubulointerstitial nephritis: single-center experience.D007378Chemicals & Drugs1633250.810934InterleukinsD013601Anatomy82238330.393288T-LymphocytesImmunologyDepartment of PediatricsPediatrics-Hem/Onc Cell & Gene TheBaylor College of MedicineCLIONAROONEYCLIONA ROONEY0.000000000000000.000000000000003578ROONEY, CLIONAProfessorAuthorship 9406591830635425Blando J, Sharma A, Higa MG, Zhao H, Vence L, Yadav SS, Kim J, Sepulveda AM, Sharp M, Maitra A, Wargo J, Tetzlaff M, Broaddus R, Katz MHG, Varadhachary GR, Overman M, Wang H, Yee C, Bernatchez C, Iacobuzio-Donahue C, Basu S, Allison JP, Sharma PProceedings of the National Academy of Sciences of the United States of AmericaComparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer. Proc Natl Acad Sci U S A. 2019 01 29; 116(5):1692-1697.Proc Natl Acad Sci U S A2019-01-11T00:00:002019Comparison of immune infiltrates in melanoma and pancreatic cancer highlights VISTA as a potential target in pancreatic cancer.HELENHESLOPHELEN HESLOP0.000000000000000.000000000000003566HESLOP, HELENProfessorSTEPHENGOTTSCHALKSTEPHEN GOTTSCHALK0.000000000000000.0000000000000053GOTTSCHALK, STEPHENAdjunct ProfessorAuthorship 9452191330995944Johnson DH, Zobniw CM, Trinh VA, Ma J, Bassett RL, Abdel-Wahab N, Anderson J, Davis JE, Joseph J, Uemura M, Noman A, Abu-Sbeih H, Yee C, Amaria R, Patel S, Tawbi H, Glitza IC, Davies MA, Wong MK, Woodman S, Hwu WJ, Hwu P, Wang Y, Diab AJournal for immunotherapy of cancerCorrection to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. J Immunother Cancer. 2019 Apr 17; 7(1):107.J Immunother Cancer2019-04-17T00:00:002019Correction to: Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis.Authorship 94561317Authorship 9458701131024520Lim SA, Kim J, Jeon S, Shin MH, Kwon J, Kim TJ, Im K, Han Y, Kwon W, Kim SW, Yee C, Kim SJ, Jang JY, Lee KMFrontiers in immunologyDefective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients. Front Immunol. 2019; 10:496.Front Immunol2019-04-09T00:00:002019Defective Localization With Impaired Tumor Cytotoxicity Contributes to the Immune Escape of NK Cells in Pancreatic Cancer Patients.31028278Chu F, Li HS, Liu X, Cao J, Ma W, Ma Y, Weng J, Zhu Z, Cheng X, Wang Z, Liu J, Jiang ZY, Luong AU, Peng W, Wang J, Balakrishnan K, Yee C, Dong C, Davis RE, Watowich SS, Neelapu SSLeukemiaCXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity. Leukemia. 2019 11; 33(11):2640-2653.Leukemia2019-04-25T00:00:002019CXCR5+CD8+ T cells are a distinct functional subset with an antitumor activity.Authorship 94712612Authorship 9482591031096717Conley AP, Wang WL, Livingston JA, Ravi V, Tsai JW, Ali A, Ingram DR, Lowery CD, Roland CL, Somaiah N, Hwu P, Yee C, Subbiah V, Futreal A, Lazar AJ, Patel S, Roszik JCancersMAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma. Cancers (Basel). 2019 May 15; 11(5).Cancers (Basel)2019-05-15T00:00:002019MAGE-A3 is a Clinically Relevant Target in Undifferentiated Pleomorphic Sarcoma/Myxofibrosarcoma.31171504Zhang S, Kohli K, Black RG, Yao L, Spadinger SM, He Q, Pillarisetty VG, Cranmer LD, Van Tine BA, Yee C, Pierce RH, Riddell SR, Jones RL, Pollack SMCancer immunology researchSystemic Interferon-? Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial. Cancer Immunol Res. 2019 08; 7(8):1237-1243.Cancer Immunol Res2019-06-06T00:00:002019Systemic Interferon-? Increases MHC Class I Expression and T-cell Infiltration in Cold Tumors: Results of a Phase 0 Clinical Trial.Authorship 950928629773224Fan J, Liang H, Shen T, Wang S, Ji X, Yee C, Lu F, Shao YCellular immunologyEarly Env-specific CTLs effectively suppress viral replication in SHIV controller macaques. Cell Immunol. 2018 09; 331:30-37.Cell Immunol2018-05-05T00:00:002018Early Env-specific CTLs effectively suppress viral replication in SHIV controller macaques.Authorship 9524471131332204Kim TJ, Park G, Kim J, Lim SA, Kim J, Im K, Shin MH, Fu YX, Del Rio ML, Rodriguez-Barbosa JI, Yee C, Suh KS, Kim SJ, Ha SJ, Lee KMNature communicationsCD160 serves as a negative regulator of NKT cells in acute hepatic injury. Nat Commun. 2019 07 22; 10(1):3258.Nat Commun2019-07-22T00:00:002019CD160 serves as a negative regulator of NKT cells in acute hepatic injury.true1ProfessorProfessortrue1ProfessorProfessorAuthorship 961142331099621Ott PA, Dotti G, Yee C, Goff SLAmerican Society of Clinical Oncology educational book. American Society of Clinical Oncology. Annual MeetingAn Update on Adoptive T-Cell Therapy and Neoantigen Vaccines. Am Soc Clin Oncol Educ Book. 2019 Jan; 39:e70-e78.Am Soc Clin Oncol Educ Book2019-05-17T00:00:002019An Update on Adoptive T-Cell Therapy and Neoantigen Vaccines.Authorship 961401931753014Safa H, Johnson DH, Trinh VA, Rodgers TE, Lin H, Suarez-Almazor ME, Fa'ak F, Saberian C, Yee C, Davies MA, Tummala S, Woodman K, Abdel-Wahab N, Diab AJournal for immunotherapy of cancerImmune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature. J Immunother Cancer. 2019 11 21; 7(1):319.J Immunother Cancer2019-11-21T00:00:002019Immune checkpoint inhibitor related myasthenia gravis: single center experience and systematic review of the literature.Authorship 9753652231915197Mondello P, Tadros S, Teater M, Fontan L, Chang AY, Jain N, Yang H, Singh S, Ying HY, Chu CS, Ma MCJ, Toska E, Alig S, Durant M, de Stanchina E, Ghosh S, Mottok A, Nastoupil L, Neelapu SS, Weigert O, Inghirami G, Baselga J, Younes A, Yee C, Dogan A, Scheinberg DA, Roeder RG, Melnick AM, Green MRCancer discoverySelective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma. Cancer Discov. 2020 03; 10(3):440-459.Cancer Discov2020-01-08T00:00:002020Selective Inhibition of HDAC3 Targets Synthetic Vulnerabilities and Activates Immune Surveillance in Lymphoma.Authorship 9766491131992715Song KH, Oh SJ, Kim S, Cho H, Lee HJ, Song JS, Chung JY, Cho E, Lee J, Jeon S, Yee C, Lee KM, Hewitt SM, Kim JH, Woo SR, Kim TWNature communicationsHSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors. Nat Commun. 2020 Jan 28; 11(1):562.Nat Commun2020-01-28T00:00:002020HSP90A inhibition promotes anti-tumor immunity by reversing multi-modal resistance and stem-like property of immune-refractory tumors.Authorship 9792611132179091Ma Y, Li J, Wang H, Chiu Y, Kingsley CV, Fry D, Delaney SN, Wei SC, Zhang J, Maitra A, Yee CGastroenterologyCombination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer. Gastroenterology. 2020 07; 159(1):306-319.e12.Gastroenterology2020-03-14T00:00:002020Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.Authorship 9800881132213626Wang J, Hasan F, Frey AC, Li HS, Park J, Pan K, Haymaker C, Bernatchez C, Lee DA, Watowich SS, Yee CCancer immunology researchHistone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells. Cancer Immunol Res. 2020 06; 8(6):794-805.Cancer Immunol Res2020-03-25T00:00:002020Histone Deacetylase Inhibitors and IL21 Cooperate to Reprogram Human Effector CD8+ T Cells to Memory T Cells.Authorship 9867461132269142Schroeder BA, Black RG, Spadinger S, Zhang S, Kohli K, Cao J, Mantilla JG, Conrad EU, Riddell SR, Jones RL, Yee C, Pollack SMJournal for immunotherapy of cancerHistiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy. J Immunother Cancer. 2020 04; 8(1).J Immunother Cancer2020-04-01T00:00:002020Histiocyte predominant myocarditis resulting from the addition of interferon gamma to cyclophosphamide-based lymphodepletion for adoptive cellular therapy.Authorship 98720511Authorship 9874433332296058Mitra A, Andrews MC, Roh W, De Macedo MP, Hudgens CW, Carapeto F, Singh S, Reuben A, Wang F, Mao X, Song X, Wani K, Tippen S, Ng KS, Schalck A, Sakellariou-Thompson DA, Chen E, Reddy SM, Spencer CN, Wiesnoski D, Little LD, Gumbs C, Cooper ZA, Burton EM, Hwu P, Davies MA, Zhang J, Bernatchez C, Navin N, Sharma P, Allison JP, Wargo JA, Yee C, Tetzlaff MT, Hwu WJ, Lazar AJ, Futreal PANature communicationsSpatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma. Nat Commun. 2020 04 15; 11(1):1839.Nat Commun2020-04-15T00:00:002020Spatially resolved analyses link genomic and immune diversity and reveal unfavorable neutrophil activation in melanoma.30008369Chua CYX, Jain P, Susnjar A, Rhudy J, Folci M, Ballerini A, Gilbert A, Singh S, Bruno G, Filgueira CS, Yee C, Butler EB, Grattoni AJournal of controlled release : official journal of the Controlled Release SocietyNanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer. J Control Release. 2018 09 10; 285:23-34.J Control Release2018-07-03T00:00:002018Nanofluidic drug-eluting seed for sustained intratumoral immunotherapy in triple negative breast cancer.Authorship 9959778Authorship 9962281432762616Kim S, Cho H, Hong SO, Oh SJ, Lee HJ, Cho E, Woo SR, Song JS, Chung JY, Son SW, Yoon SM, Jeon YM, Jeon S, Yee C, Lee KM, Hewitt SM, Kim JH, Song KH, Kim TWAutophagyLC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells. Autophagy. 2021 08; 17(8):1978-1997.Autophagy2020-08-14T00:00:002020LC3B upregulation by NANOG promotes immune resistance and stem-like property through hyperactivation of EGFR signaling in immune-refractory tumor cells.32743568An X, Martinez-Paniagua M, Rezvan A, Fathi M, Singh S, Biswas S, Pourpak M, Yee C, Liu X, Varadarajan NbioRxiv : the preprint server for biologySingle-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. bioRxiv. 2020 Jul 23.bioRxiv2020-07-23T00:00:002020Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2.Authorship 1002150633020246Lin JS, Wang DY, Mamlouk O, Glass WF, Abdelrahim M, Yee C, Abudayyeh AJournal for immunotherapy of cancerImmune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab. J Immunother Cancer. 2020 10; 8(2).J Immunother Cancer2020-10-01T00:00:002020Immune checkpoint inhibitor associated reactivation of primary membranous nephropathy responsive to rituximab.Authorship 10032903133087697Bradley SD, Talukder AH, Lai I, Davis R, Alvarez H, Tiriac H, Zhang M, Chiu Y, Melendez B, Jackson KR, Katailiha A, Sonnemann HM, Li F, Kang Y, Qiao N, Pan BF, Lorenzi PL, Hurd M, Mittendorf EA, Peterson CB, Javle M, Bristow C, Kim M, Tuveson DA, Hawke D, Kopetz S, Wolff RA, Hwu P, Maitra A, Roszik J, Yee C, Liz?e GNature communicationsVestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers. Nat Commun. 2020 10 21; 11(1):5332.Nat Commun2020-10-21T00:00:002020Vestigial-like 1 is a shared targetable cancer-placenta antigen expressed by pancreatic and basal-like breast cancers.Authorship 101162118Authorship 10125221233589527Hou J, Wang Y, Shi L, Chen Y, Xu C, Saeedi A, Pan K, Bohat R, Egan NA, McKenzie JA, Mbofung RM, Williams LJ, Yang Z, Sun M, Liang X, Rodon Ahnert J, Varadarajan N, Yee C, Chen Y, Hwu P, Peng WJournal for immunotherapy of cancerIntegrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators. J Immunother Cancer. 2021 02; 9(2).J Immunother Cancer2021-02-01T00:00:002021Integrating genome-wide CRISPR immune screen with multi-omic clinical data reveals distinct classes of tumor intrinsic immune regulators.33643693Lin JS, Mamlouk O, Selamet U, Tchakarov A, Glass WF, Sheth RA, Layman RM, Dadu R, Abdelwahab N, Abdelrahim M, Diab A, Yee C, Abudayyeh AOncoimmunologyInfliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis. Oncoimmunology. 2021 02 02; 10(1):1877415.Oncoimmunology2021-02-02T00:00:002021Infliximab for the treatment of patients with checkpoint inhibitor-associated acute tubular interstitial nephritis.Authorship 1017314633920906Lim SA, Moon Y, Shin MH, Kim TJ, Chae S, Yee C, Hwang D, Park H, Lee KMCancersHypoxia-Driven HIF-1a Activation Reprograms Pre-Activated NK Cells towards Highly Potent Effector Phenotypes via ERK/STAT3 Pathways. Cancers (Basel). 2021 Apr 15; 13(8).Cancers (Basel)2021-04-15T00:00:002021Hypoxia-Driven HIF-1a Activation Reprograms Pre-Activated NK Cells towards Highly Potent Effector Phenotypes via ERK/STAT3 Pathways.Authorship 10179202133963013Kohli K, Yao L, Nowicki TS, Zhang S, Black RG, Schroeder BA, Farrar EA, Cao J, Sloan H, Stief D, Cranmer LD, Wagner MJ, Hawkins DS, Pillarisetty VG, Ribas A, Campbell J, Pierce RH, Kim EY, Jones RL, Riddell SR, Yee C, Pollack SMJournal for immunotherapy of cancerIL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy. J Immunother Cancer. 2021 05; 9(5).J Immunother Cancer2021-05-01T00:00:002021IL-15 mediated expansion of rare durable memory T cells following adoptive cellular therapy.Authorship 10190961534021033Saberian C, Amaria RN, Najjar AM, Radvanyi LG, Haymaker CL, Forget MA, Bassett RL, Faria SC, Glitza IC, Alvarez E, Parshottam S, Prieto V, Liz?e G, Wong MK, McQuade JL, Diab A, Yee C, Tawbi HA, Patel S, Shpall EJ, Davies MA, Hwu P, Bernatchez CJournal for immunotherapy of cancerRandomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma. J Immunother Cancer. 2021 05; 9(5).J Immunother Cancer2021-05-01T00:00:002021Randomized phase II trial of lymphodepletion plus adoptive cell transfer of tumor-infiltrating lymphocytes, with or without dendritic cell vaccination, in patients with metastatic melanoma.Authorship 1019275534027895Hasan F, Chiu Y, Shaw RM, Wang J, Yee CJCI insightHypoxia acts as an environmental cue for the human tissue-resident memory T cell differentiation program. JCI Insight. 2021 05 24; 6(10).JCI Insight2021-05-24T00:00:002021Hypoxia acts as an environmental cue for the human tissue-resident memory T cell differentiation program.Authorship 1020693934104543Abdelrahim M, Mamlouk O, Lin H, Lin J, Page V, Abdel-Wahab N, Swan J, Selamet U, Yee C, Diab A, Suki W, Abudayyeh AOncoimmunologyIncidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis. Oncoimmunology. 2021 05 23; 10(1):1927313.Oncoimmunology2021-05-23T00:00:002021Incidence, predictors, and survival impact of acute kidney injury in patients with melanoma treated with immune checkpoint inhibitors: a 10-year single-institution analysis.Authorship 102363732Authorship 1024305934244308Li F, Deng L, Jackson KR, Talukder AH, Katailiha AS, Bradley SD, Zou Q, Chen C, Huo C, Chiu Y, Stair M, Feng W, Bagaev A, Kotlov N, Svekolkin V, Ataullakhanov R, Miheecheva N, Frenkel F, Wang Y, Zhang M, Hawke D, Han L, Zhou S, Zhang Y, Wang Z, Decker WK, Sonnemann HM, Roszik J, Forget MA, Davies MA, Bernatchez C, Yee C, Bassett R, Hwu P, Du X, Lizee GJournal for immunotherapy of cancerNeoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations. J Immunother Cancer. 2021 07; 9(7).J Immunother Cancer2021-07-01T00:00:002021Neoantigen vaccination induces clinical and immunologic responses in non-small cell lung cancer patients harboring EGFR mutations.34205020Mueller-Schoell A, Puebla-Osorio N, Michelet R, Green MR, K?nkele A, Huisinga W, Strati P, Chasen B, Neelapu SS, Yee C, Kloft CCancersEarly Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model. Cancers (Basel). 2021 Jun 03; 13(11).Cancers (Basel)2021-06-03T00:00:002021Early Survival Prediction Framework in CD19-Specific CAR-T Cell Immunotherapy Using a Quantitative Systems Pharmacology Model.Authorship 10262601034312620Pan K, Chiu Y, Huang E, Chen M, Wang J, Lai I, Singh S, Shaw R, MacCoss M, Yee CbioRxiv : the preprint server for biologyImmunogenic SARS-CoV2 Epitopes Defined by Mass Spectrometry. bioRxiv. 2021 Jul 21.bioRxiv2021-07-21T00:00:002021Immunogenic SARS-CoV2 Epitopes Defined by Mass Spectrometry.Authorship 1028796934462731An X, Martinez-Paniagua M, Rezvan A, Sefat SR, Fathi M, Singh S, Biswas S, Pourpak M, Yee C, Liu X, Varadarajan NiScienceSingle-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2. iScience. 2021 Sep 24; 24(9):103037.iScience2021-08-26T00:00:002021Single-dose intranasal vaccination elicits systemic and mucosal immunity against SARS-CoV-2.Authorship 103334318Authorship 10335451034822775Li H, Xiao Y, Li Q, Yao J, Yuan X, Zhang Y, Yin X, Saito Y, Fan H, Li P, Kuo WL, Halpin A, Gibbons DL, Yagita H, Zhao Z, Pang D, Ren G, Yee C, Lee JJ, Yu DCancer cellThe allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1. Cancer Cell. 2022 01 10; 40(1):36-52.e9.Cancer Cell2021-11-24T00:00:002021The allergy mediator histamine confers resistance to immunotherapy in cancer patients via activation of the macrophage histamine receptor H1.34725257Pan K, Chiu Y, Huang E, Chen M, Wang J, Lai I, Singh S, Shaw RM, MacCoss MJ, Yee CProceedings of the National Academy of Sciences of the United States of AmericaMass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs. Proc Natl Acad Sci U S A. 2021 11 16; 118(46).Proc Natl Acad Sci U S A2021-11-16T00:00:002021Mass spectrometric identification of immunogenic SARS-CoV-2 epitopes and cognate TCRs.Authorship 10408831535190823Creasy CA, Meng YJ, Forget MA, Karpinets T, Tomczak K, Stewart C, Torres-Cabala CA, Pilon-Thomas S, Sarnaik AA, Mul? JJ, Garraway L, Bustos M, Zhang J, Patel SP, Diab A, Glitza IC, Yee C, Tawbi H, Wong MK, McQuade J, Hoon DSB, Davies MA, Hwu P, Amaria RN, Haymaker C, Beroukhim R, Bernatchez CClinical cancer research : an official journal of the American Association for Cancer ResearchGenomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma. Clin Cancer Res. 2022 05 02; 28(9):1911-1924.Clin Cancer Res2022-05-02T00:00:002022Genomic Correlates of Outcome in Tumor-Infiltrating Lymphocyte Therapy for Metastatic Melanoma.Authorship 1044154935440620Lee HJ, Song KH, Oh SJ, Kim S, Cho E, Kim J, Park YG, Lee KM, Yee C, Song SH, Chang S, Choi J, Jung ST, Kim TWNature communicationsTargeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes. Nat Commun. 2022 04 19; 13(1):2127.Nat Commun2022-04-19T00:00:002022Targeting TCTP sensitizes tumor to T cell-mediated therapy by reversing immune-refractory phenotypes.Authorship 10457543035537412Hailemichael Y, Johnson DH, Abdel-Wahab N, Foo WC, Bentebibel SE, Daher M, Haymaker C, Wani K, Saberian C, Ogata D, Kim ST, Nurieva R, Lazar AJ, Abu-Sbeih H, Fa'ak F, Mathew A, Wang Y, Falohun A, Trinh V, Zobniw C, Spillson C, Burks JK, Awiwi M, Elsayes K, Soto LS, Melendez BD, Davies MA, Wargo J, Curry J, Yee C, Lizee G, Singh S, Sharma P, Allison JP, Hwu P, Ekmekcioglu S, Diab ACancer cellInterleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity. Cancer Cell. 2022 05 09; 40(5):509-523.e6.Cancer Cell2022-05-09T00:00:002022Interleukin-6 blockade abrogates immunotherapy toxicity and promotes tumor immunity.Authorship 10470771235653194Zamler DB, Shingu T, Kahn LM, Huntoon K, Kassab C, Ott M, Tomczak K, Liu J, Li Y, Lai I, Zorilla-Veloz R, Yee C, Rai K, Kim BY, Watowich SS, Heimberger AB, Draetta GF, Hu JJCI insightImmune landscape of a genetically engineered murine model of glioma compared with human glioma. JCI Insight. 2022 06 22; 7(12).JCI Insight2022-06-22T00:00:002022Immune landscape of a genetically engineered murine model of glioma compared with human glioma.Authorship 10622795Authorship 10568988Authorship 106178715Authorship 10552701036185804Singh S, Clemente LC, Parra ER, Tchakarov A, Yang C, Li Y, Long JP, Yee C, Lin JSOncoimmunologyUrinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates. Oncoimmunology. 2022; 11(1):2124678.Oncoimmunology2022-09-22T00:00:002022Urinary T cells are detected in patients with immune checkpoint inhibitor-associated immune nephritis that are clonotypically identical to kidney T cell infiltrates.36518525Hou J, Liang S, Xu C, Wei Y, Wang Y, Tan Y, Sahni N, McGrail DJ, Bernatchez C, Davies M, Li Y, Chen R, Yi SS, Chen Y, Yee C, Chen K, Peng WNAR cancerSingle-cell CRISPR immune screens reveal immunological roles of tumor intrinsic factors. NAR Cancer. 2022 Dec; 4(4):zcac038.NAR Cancer2022-12-09T00:00:002022Single-cell CRISPR immune screens reveal immunological roles of tumor intrinsic factors.36220826Huuhtanen J, Chen L, Jokinen E, Kasanen H, L?nnberg T, Kreutzman A, Peltola K, Hernberg M, Wang C, Yee C, L?hdesm?ki H, Davis MM, Mustjoki SNature communicationsEvolution and modulation of antigen-specific T cell responses in melanoma patients. Nat Commun. 2022 10 11; 13(1):5988.Nat Commun2022-10-11T00:00:002022Evolution and modulation of antigen-specific T cell responses in melanoma patients.36472921Singh S, Long JP, Tchakarov A, Dong Y, Yee C, Lin JSJCI insightTertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis. JCI Insight. 2022 Dec 01.JCI Insight2022-12-01T00:00:002022Tertiary lymphoid structure signatures are associated with immune checkpoint inhibitor related acute interstitial nephritis.Authorship 10674412136997799Glitza Oliva IC, Ferguson SD, Bassett R, Foster AP, John I, Hennegan TD, Rohlfs M, Richard J, Iqbal M, Dett T, Lacey C, Jackson N, Rodgers T, Phillips S, Duncan S, Haydu L, Lin R, Amaria RN, Wong MK, Diab A, Yee C, Patel SP, McQuade JL, Fischer GM, McCutcheon IE, O'Brien BJ, Tummala S, Debnam M, Guha-Thakurta N, Wargo JA, Burton EM, Tawbi HA, Davies MANature medicineConcurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results. Nat Med. 2023 04; 29(4):898-905.Nat Med2023-03-30T00:00:002023Concurrent intrathecal and intravenous nivolumab in leptomeningeal disease: phase 1 trial interim results.Authorship 1068624237094987Mc Laughlin AM, Yee CJournal for immunotherapy of cancerLetter to the editor: Quality criteria for computational models predicting individual outcomes in CAR-T cell therapy. J Immunother Cancer. 2023 04; 11(4).J Immunother Cancer2023-04-01T00:00:002023Letter to the editor: Quality criteria for computational models predicting individual outcomes in CAR-T cell therapy.true1Adjunct ProfessorAdjunct ProfessorAuthorship 107342644Authorship 10720693237419119Wang R, Song S, Qin J, Yoshimura K, Peng F, Chu Y, Li Y, Fan Y, Jin J, Dang M, Dai E, Pei G, Han G, Hao D, Li Y, Chatterjee D, Harada K, Pizzi MP, Scott AW, Tatlonghari G, Yan X, Xu Z, Hu C, Mo S, Shanbhag N, Lu Y, Sewastjanow-Silva M, Fouad Abdelhakeem AA, Peng G, Hanash SM, Calin GA, Yee C, Mazur P, Marsden AN, Futreal A, Wang Z, Cheng X, Ajani JA, Wang LCancer cellEvolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression. Cancer Cell. 2023 08 14; 41(8):1407-1426.e9.Cancer Cell2023-07-06T00:00:002023Evolution of immune and stromal cell states and ecotypes during gastric adenocarcinoma progression.37248301Chu Y, Dai E, Li Y, Han G, Pei G, Ingram DR, Thakkar K, Qin JJ, Dang M, Le X, Hu C, Deng Q, Sinjab A, Gupta P, Wang R, Hao D, Peng F, Yan X, Liu Y, Song S, Zhang S, Heymach JV, Reuben A, Elamin YY, Pizzi MP, Lu Y, Lazcano R, Hu J, Li M, Curran M, Futreal A, Maitra A, Jazaeri AA, Ajani JA, Swanton C, Cheng XD, Abbas HA, Gillison M, Bhat K, Lazar AJ, Green M, Litchfield K, Kadara H, Yee C, Wang LNature medicinePan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance. Nat Med. 2023 Jun; 29(6):1550-1562.Nat Med2023-05-29T00:00:002023Pan-cancer T cell atlas links a cellular stress response state to immunotherapy resistance.Authorship 1084280337448343Mc Laughlin AM, Milligan PA, Yee C, Bergstrand MCPT: pharmacometrics & systems pharmacologyModel-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling. CPT Pharmacometrics Syst Pharmacol. 2023 Nov; 12(11):1577-1590.CPT Pharmacometrics Syst Pharmacol2023-07-28T00:00:002023Model-informed drug development of autologous CAR-T cell therapy: Strategies to optimize CAR-T cell exposure leveraging cell kinetic/dynamic modeling.Authorship 10850482738105939Han Y, Yang Y, Tian Y, Fattah FJ, von Itzstein MS, Hu Y, Zhang M, Kang X, Yang DM, Liu J, Xue Y, Liang C, Raman I, Zhu C, Xiao O, Dowell JE, Homsi J, Rashdan S, Yang S, Gwin ME, Hsiehchen D, Gloria-McCutchen Y, Pan K, Wu F, Gibbons D, Wang X, Yee C, Huang J, Reuben A, Cheng C, Zhang J, Gerber DE, Wang TbioRxiv : the preprint server for biologypan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding. bioRxiv. 2023 Dec 12.bioRxiv2023-12-12T00:00:002023pan-MHC and cross-Species Prediction of T Cell Receptor-Antigen Binding.Authorship 1089243538385283Leyva-Aranda V, Singh S, Telesforo MJ, Young S, Yee C, Hartgerink JDACS biomaterials science & engineeringNanofibrous MultiDomain Peptide Hydrogels Provide T Cells a 3D, Cytocompatible Environment for Cell Expansion and Antigen-Specific Killing. ACS Biomater Sci Eng. 2024 Mar 11; 10(3):1448-1460.ACS Biomater Sci Eng2024-02-22T00:00:002024Nanofibrous MultiDomain Peptide Hydrogels Provide T Cells a 3D, Cytocompatible Environment for Cell Expansion and Antigen-Specific Killing.true1ProfessorProfessortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1InstructorInstructortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1Associate ProfessorAssociate Professor